XASE · NSRX
-5.14% · -$0.1800 · Vol 19.9K
After hours · updated 16:10:00 ET
Nasus Pharma Ltd.

Nasus Pharma Ltd.

$3.32
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
NSRX
Nasus Pharma Ltd.
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

50/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NSRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NSRX catalysts
About Nasus Pharma Ltd.
Listed since
2025
Employees
7
Country
US

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.47
Day high
$3.57
Day low
$3.15
Previous close
$3.50
52W high
$9.15
-63.72% from high
52W low
$2.01
18% of range
Market cap
$41M
Beta
1.81
Shares out
11.7M
Volume
19.9K
1.21× rel vol
Avg volume
16.5K
VWAP
$3.27
Price history computed in-house
1W
+3.43%
1M
-3.35%
3M
-2.06%
YTD
-63.72%
SMA 50 $3.15 · above
SMA 200 $4.81 · below
52W position 18%

NSRX overview

Veridion Score
50
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NSRX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NSRX Form 4 filings
Public disclosures

Congress activity in NSRX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NSRX in the cached public ledger.

Federal contracts

NSRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NSRX in this window.
Lobbying spend

NSRX lobbying filings, year to date.

Registered lobbying filings matched to Nasus Pharma Ltd..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NSRX in this window.
Loading news for NSRX
Analyst ratings
Sovereign unlock shows live analyst consensus for NSRX.
Options
Sovereign unlock shows live options positioning for NSRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.